Respiratory Flashcards
Pneumonia
Aetiology (4)
Community acquired pneumonia: primary or secondary to underlying disease, Strep pneumoniae –> Haemophilus influenzae –> Mycoplasma pneumoniae –> viruses account for 15%
Hospital acquired (nosocomial, >48hr after admission): gram -ve or Staph aureus
Aspiration: stroke, reduced consciousness, oesophageal disease
Immunocompromised patients
Pneumonia
Signs + Symptoms (12)
Malaise Fever Riggers Dyspnoea Cough and purulent sputum Haemoptysis Pleuritic chest pain Cyanosis Confusion (may be only sign in elderly) Hypotension Signs of consolidation: reduced expansion, dull percussion, increased vocal resonance, bronchial breathing Pleural rub
Pneumonia
Investigations (5)
CXR: lobar/multilobular infiltrates, pleural effusion
Assess saturation: O2 sats, ABG if severe, BP
Bloods: FBC, U&E, LFT, CRP, blood culture
Sputum: microscopy + culture
Legionella (sputum culture and urinary antigen) if severe
Pneumonia
Severity (8)
Confusion (abbreviated mental test <8) Ureal (>7mmol/l) Respiratory rate (>30/min) BP (<90 systolic or <60 diastolic) Age >65
0-1: home with/without treatment
2: hospital therapy
3+: severe, consider ITU
Pneumonia
Treatment (7)
CURB 0-1: oral amoxicillin or clarithromycin or doxycycline
CURB 2: oral amoxicillin + clarithromycin or doxycycline (IV may be required)
CURB 3+: co-amoxiclav IV or cephalosporin IV and clarithromycin IV, add flucloxacillin +/- rifampicin if Staph suspected or vancomycin if MRSA suspected
Analgesia for pleurisy
O2 if sats <94%
IV fluids
VTE prophylaxis
Pneumonia
Complications (5)
Respiratory failure: aim sats 94-98%
Hypotension: due to dehydration and vasodilatation, give IV fluids
Pleural effusion: inflammation of pleura by adjacent pneumonia causing fluid exudation into pleural space
Empyema: pus in pleural space, suspect in patients with resolving pneumonia developing fever
Lung abscess
Septicaemia
Cystic Fibrosis
Aetiology (3)
Mutations in CFTR gene on chromosome 7
Cl- channel defect leads to defective chloride secretion and increased sodium absorption across airway epithelium
Autosomal recessive
Cystic Fibrosis
Signs + Symptoms (7)
In neonates: failure to thrive, meconium ileum, rectal prolapse
Cough
Wheeze
Recurrent infections
Cor pulmonale
Pancreatic insufficiency (diabetes, steatorrhoea)
Male infertility
Cystic Fibrosis
Investigations (5)
Sweat test: sodium + chloride >60mmol/l Genetics screen Heel prick test (5 days old) CXR: hyperinflation, bronchiectasis Spirometry: obstructive pattern
Cystic Fibrosis
Treatment (7)
Regular chest physio
Antibiotics for acute infective exacerbations and prophylaxis
Mucolytics eg. DNase
Bronchodilators
Pancreatic enzyme replacement
Vitamine supplements (ADEK)
If advanced: non-invasive ventilation/transplant
Cystic Fibrosis
Common bacterial infections (2)
Pseudomonas aeruginosa in adulthood
Staph aureus + H.influenzae in children
Bronchiectasis
Definition (1)
Chronic infection of the bronchi and bronchioles leading to permanent dilation
Bronchiectasis Main organisms (4)
H. influenzae
Strep pneumoniae
Staph aureus
Pseudomonas aeruginosa
Bronchiectasis
Aetiology (4)
Congenital: CF
Post infection: pneumonia, TB, HIV
Bronchial obstruction: tumour, foreign body
Allergic bronchopulmonary aspergillosis
Bronchiectasis
Signs + Symptoms (4)
Persistent cough and sputum
Finger clubbing
Coarse inspiratory crepitations
Wheeze
Bronchiectasis
Complications (3)
Pneumonia
Pleural effusion
Pneumothorax
Bronchiectasis
Investigations (6)
Sputum culture
CXR: thickened bronchial walls
HRCT chest: assess extent and distribution of disease
Spirometry: obstructive pattern
Bronchoscopy: obtain samples, exclude obstruction
CF sweat test
Bronchiectasis
Treatment (5)
Postural drainage Chest physio Antibiotics Bronchodilators if asthma, COPD, CF, allergic bronchopulmonary aspergillosis Corticosteroids if ABPA
Pulmonary Aspergillus Infection
Effects of Aspergillus on the lung (5)
Asthma (type 1 hypersensitivity to fungal spores)
Allergic bronchopulmonary aspergillosis (causes bronchiectasis, give steroids)
Aspergilloma (fungus ball within pre-existing cavity)
Invasive aspergillosis
Extrinsic allergic alveoli’s
Lung Cancer Risk factors (3)
Smoking
Asbestos
Radiation
Lung Cancer
Pathology (2)
Non-Small Cell Lung Cancer: squamous, adenocarcinoma, large cell undifferentiated
Small Cell Lung Cancer: endocrine
Lung Cancer
Signs + Symptoms (8)
Cough Haemoptysis Dyspnoea Chest pain Weight loss Anaemia Clubbing Metastatic signs (bone tenderness, hepatomegaly, confusion, fits)
Lung Cancer
Sites of metastatic spread (4)
Liver
Adrenal glands
Brain
Bone
Lung Cancer
Complications (3)
Recurrent laryngeal nerve palsy
Phrenic nerve palsy
SVC obstruction
Lung Cancer
Investigations (6)
Cytology: sputum and pleural fluid
CXR: hilar enlargement, consolidation, collapse, pleural effusion
Fine needle aspiration or biopsy of peripheral lesions/superficial lymph nodes
CT: staging
PET: staging
Bronchoscopy: to give histology and assess operability
Lung Cancer
Staging (11)
T1: <3cm
T2: >3cm
T3: close to carina or involving chest wall/diaphragm
T4: involves carina, mediastinum, heart, great vessels, trachea, oesophagus
N0: no nodes
N1: peribronchial and/or ipsilateral hilum
N2: ipsilateral mediastinum
N3: contralateral
M0: none
M1a: in other lung
M1b: distant metastases
Lung Cancer
Treatment (3)
NSCLC: stage 1/2 surgery, curative radio if respiratory reserve is poor, chemo +/- radio if advanced
SCLC: chemo but relapse rate high and mortality high
Palliation: radio for bronchial/SVC obstruction or haemoptysis
Lung Cancer
Prognosis (2)
NSCLC: 50% 2 year survival without spread, 10% with spread
SCLC: survive 3 months if untreated, 1-1.5 years if treated
Acute Respiratory Distress Syndrome
Definition (2)
May be due to direct lung injury or secondary to severe systemic illness
Lung damage and release of inflammatory mediators cause increase in capillary permeability and pulmonary oedema, often associated with multi organ failure
Acute Respiratory Distress Syndrome
Aetiology (4)
Pulmonary: pneumonia, injury, inhalation
Shock
Haemorrhage
Septicaemia
Acute Respiratory Distress Syndrome Risk Factors (6)
Sepsis Hypovolaemic shock Trauma Burns and smoke inhalation Diabetic ketoacidosis Pneumonia
Acute Respiratory Distress Syndrome
Signs + Symptoms (5)
Cyanosis Tachypnoea Tachycardia Peripheral vasoldilatation Bilateral inspiratory crackles
Acute Respiratory Distress Syndrome
Investigations (3)
Bloods: FBC, U+E, LFT, amylase, clotting, CRP, blood cultures
ABG
CXR: bilateral pulmonary infiltrates
Acute Respiratory Distress Syndrome
Treatment (5)
Admit to ITU
Respiratory support: CPAP/mechanical ventilation
Circulatory support: inotropes (eg. dobutamine), vasodilators, transfusion
Sepsis: identity organism and treat accordingly
Steroids for subacute
Asthma
Definition (1)
Recurrent episodes of dyspnoea, cough and wheeze caused by reversible airway obstruction
Asthma
Pathology (3)
Bronchial muscle contraction, triggered by a variety of stimuli
Mucosal swelling/inflammation, caused by mast cel and basophil degranulation resulting in release of inflammatory mediators
Increased mucus production
Asthma
Symptoms (6)
Intermittent dyspnoea, wheeze, cough (often nocturnal) and sputum
Precipitants: cold air, exercise, allergens (home dust mite, pollen, fur), smoking, B-blockers
Diurnal variation
Disturbed sleep
Acid reflux
Other atopic disease eg. eczema, hay fever
Asthma
Signs (7)
Tachypnoea
Wheeze
Hyperinflated chest
Hyperresonant percussion
Severe attack: inability to complete sentences, pulse >110bpm, RR >25
Life-threatening attack: silent chest, confusion, exhaustion, cyanosis, bradycardia
Near fatal: high PaCO2
Asthma
Investigations for chronic (4)
PEF monitoring
Spirometry: obstructive defect (low FV1/FVC)
CXR: hyperinflation
Skin prick test may help identify allergens
Asthma
Investigations for attack (5)
PEF Sputum culture Bloods: FBC, U&E, CRP, cultures ABG CXR: to exclude infection/pneumothorax
Asthma Chronic treatment (5)
Step 1: SABA as required (unless using MART), consider starting low-dose ICS
Step 2: regular preventer (low-dose ICS) + SABA as required
Step 3: initial add-on therapy (add inhaled LABA to low-dose ICS- fixed dose or MART) + SABA as required
Step 4: additional controller therapies (increase ICS to medium dose or add LTRA), if no response to LABA then stop + SABA as required
Step 5: specialist therapies (high dose ICS + oral steroids)